Vimarsana
Biggest News Aggregation in the World

Merck Sharp Dohme News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Merck Sharp Dohme. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Merck Sharp Dohme Today - Breaking & Trending Today

Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting - Vimarsana News

Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 clinical trial evaluating olomorasib as a monotherapy in...

TME Pharma N.V.: TME Pharma Announces Convocation of the 2024 Annual General Meeting of Shareholders - Vimarsana News

TME Pharma N.V.: TME Pharma Announces Convocation of the 2024 Annual General Meeting of Shareholders

Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME) (Paris:ALTME),a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment

Evaxion Biotech A/S to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024 - Vimarsana News

Evaxion Biotech A/S to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024

Evaxion Biotech A/S announced its participation in the American Society of Clinical Oncology Annual Meeting, where it will present positive immune data form its ongoing EVX-01 Phase 2 study. The...

Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024 - Vimarsana News

Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024

TOKYO, May 23, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society

Evaxion Biotech: Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024 - Vimarsana News

Evaxion Biotech: Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024

EVX-01 induced positive clinically relevant immune responses in all assessed patientsBooster immunizations tended to increase the immune responseThe observed immune responses were mediated by both CD4+